Measured in a cell inhibition assay using A431 cell. The expected IC50 is 2.3 ng/ml.
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | Pro-epidermal growth factor, EGF, Epidermal growth factor, Urogastrone |
| Accession | P01133 |
| Amino Acid Sequence | Asn971-Arg1023 |
| Expression System | E.coli |
| Molecular Weight | 10 kDa (Reducing) |
| Purity | >95% by SDS-PAGE & HPLC. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Chevalier RL, Goyal S, Thornhill BA. 1999. J Urol, 162: 1532-6. |
Background
Epidermal Growth Factor (EGF) is a potent growth factor that stimulates the proliferation of various epidermal and epithelial cells. Epidermal growth factor (EGF) binds to epidermal growth factor receptor and stimulates an intracellular signal transduction cascade, leading to activation of genes that regulate cell proliferation, angiogenesis, motility, and metastasis. Epidermal growth factor (EGF) mRNA and protein are expressed in a number of adult tissues, especially in epithelial cells in the gastrointestinal tract. Predominant sites of synthesis of this peptide are the submandibular glands, the Brunner glands in the small intestine and the kidney.
Picture
Picture
Bioactivity

EGF Protein, Human (Cat#UA040575) maintains colorectal cancer organoid growth well during multiple passages and long-term culture processes.
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
SEC-HPLC
>95% as determined by SEC-HPLC.
RP-HPLC
>95% as determined by RP-HPLC.
